Treatment Recommendations, Updates for Major Depressive Disorder

Share this content:
Aripiprazole, brexpiprazole, olanzapine, quetiapine, and risperidole are part of the treatment armamentarium for MDD.
Aripiprazole, brexpiprazole, olanzapine, quetiapine, and risperidole are part of the treatment armamentarium for MDD.
The following article is part of live conference coverage from the 2017 Psych Congress in New Orleans, Louisiana. Psychiatry Advisor's staff will be reporting breaking news associated with research conducted by leading experts in psychiatry, as well as presentations from the Congress. Visit Psychiatry Advisor's conference section for continuous coverage live from Psych Congress 2017.

NEW ORLEANS — In a presentation at the 2017 US Psych Congress, held September 16-19, Michael E. Thase, MD, professor of psychiatry at the Perelman School of Medicine of the University of Pennsylvania, discussed  updates to antidepressant management, as well as challenges faced by clinicians managing major depression in patients.

Dr Thase explored pharmacologic treatments of depression, including first-line antidepressants that are not mentioned in the most recent American Psychiatric Association (APA) guidelines from 2010. Among more recently introduced antidepressants, vilazodone 40 mg/d was found to be very potent and well-tolerated. Vortioxetine had “enhancing effects on complex cognition, not necessarily memory or concentration but perhaps multi-step sequencing,” Dr Thase said.

On the subject of adjunctive therapy, Dr Thase recommended second-generation antidepressants (SGAs) in patients who are seriously ill or incapacitated. “If you are using adjunctive strategies early on, pick a treatment that compliments the first medication and matches the patient,” he explained. An additional point Dr Thase made is that while combining antidepressants was once considered indicative of bad practice, it is now commonplace in the management of treatment-resistant depression.

Aripiprazole, brexpiprazole, olanzapine, quetiapine, and risperidole appear effective as adjunctive antidepressants, while olanzapine, quetiapine, and lurasidone are effective as monotherapy for bipolar depression. Additionally, quetiapine has established efficacy as monotherapy for major depressive disorder.

Side effects of antidepressants present significant challenges to adherence. Clinicians can manage sexual side effects by taking a history to understand dysfunction prior to treatment, treatment reduction, post-coital dosing, and antidepressant switching.  

Weight gain may be more difficult to manage. While caloric intake can be reduced and exercise encouraged, Dr Thase advises that “preventing weight gain is easier than facilitating weight loss.”


Visit Psychiatry Advisor's conference section for continuous coverage live from Psych Congress 2017.

Reference

Thase, ME. Solving clinical challenges in major depression. Presentation at: Psych Congress; September 16-19, 2017; New Orleans, LA.


You must be a registered member of Psychiatry Advisor to post a comment.

Upcoming Meetings

Sign Up for Free e-newsletters